 | • レポートコード：GIR-107A12012 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、β1アドレナリン受容体作動薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。β1アドレナリン受容体作動薬の種類別市場規模（ドブタミン、デノパミン、ザモテロール、その他）、用途別市場規模（慢性心不全、心筋梗塞、術後低血圧、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・β1アドレナリン受容体作動薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Ivax Pharmaceuticals 、Physicians Total Care、Baxter Healthcare 、Sanofi、Teva Canada、Pfizer、Bedford Laboratories、Novartis、Sterimax、Teligent ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ドブタミン、デノパミン、ザモテロール、その他 ・用途別分析2016年-2026年：慢性心不全、心筋梗塞、術後低血圧、その他 ・β1アドレナリン受容体作動薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・β1アドレナリン受容体作動薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・β1アドレナリン受容体作動薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・β1アドレナリン受容体作動薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・β1アドレナリン受容体作動薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The β1 Adrenoceptor Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global β1 Adrenoceptor Agonists size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global β1 Adrenoceptor Agonists market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
β1 Adrenoceptor Agonists market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Dobutamine
Denopamine
Xamoterol
Others
Market segment by Application, can be divided into
Chronic Heart Failure
Myocardial Infarction
Postoperative Hypotension
Others
Market segment by players, this report covers
Ivax Pharmaceuticals
Physicians Total Care
Baxter Healthcare
Sanofi
Teva Canada
Pfizer
Bedford Laboratories
Novartis
Sterimax
Teligent
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of β1 Adrenoceptor Agonists
1.2 Classification of β1 Adrenoceptor Agonists by Type
1.2.1 Overview: Global β1 Adrenoceptor Agonists Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global β1 Adrenoceptor Agonists Revenue Market Share by Type in 2020
1.2.3 Dobutamine
1.2.4 Denopamine
1.2.5 Xamoterol
1.2.6 Others
1.3 Global β1 Adrenoceptor Agonists Market by Application
1.3.1 Overview: Global β1 Adrenoceptor Agonists Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Chronic Heart Failure
1.3.3 Myocardial Infarction
1.3.4 Postoperative Hypotension
1.3.5 Others
1.4 Global β1 Adrenoceptor Agonists Market Size & Forecast
1.5 Global β1 Adrenoceptor Agonists Market Size and Forecast by Region
1.5.1 Global β1 Adrenoceptor Agonists Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global β1 Adrenoceptor Agonists Market Size by Region, (2016-2021)
1.5.3 North America β1 Adrenoceptor Agonists Market Size and Prospect (2016-2026)
1.5.4 Europe β1 Adrenoceptor Agonists Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific β1 Adrenoceptor Agonists Market Size and Prospect (2016-2026)
1.5.6 South America β1 Adrenoceptor Agonists Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa β1 Adrenoceptor Agonists Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 β1 Adrenoceptor Agonists Market Drivers
1.6.2 β1 Adrenoceptor Agonists Market Restraints
1.6.3 β1 Adrenoceptor Agonists Trends Analysis
2 Company Profiles
2.1 Ivax Pharmaceuticals
2.1.1 Ivax Pharmaceuticals Details
2.1.2 Ivax Pharmaceuticals Major Business
2.1.3 Ivax Pharmaceuticals β1 Adrenoceptor Agonists Product and Solutions
2.1.4 Ivax Pharmaceuticals β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Ivax Pharmaceuticals Recent Developments and Future Plans
2.2 Physicians Total Care
2.2.1 Physicians Total Care Details
2.2.2 Physicians Total Care Major Business
2.2.3 Physicians Total Care β1 Adrenoceptor Agonists Product and Solutions
2.2.4 Physicians Total Care β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Physicians Total Care Recent Developments and Future Plans
2.3 Baxter Healthcare
2.3.1 Baxter Healthcare Details
2.3.2 Baxter Healthcare Major Business
2.3.3 Baxter Healthcare β1 Adrenoceptor Agonists Product and Solutions
2.3.4 Baxter Healthcare β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Baxter Healthcare Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi β1 Adrenoceptor Agonists Product and Solutions
2.4.4 Sanofi β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Teva Canada
2.5.1 Teva Canada Details
2.5.2 Teva Canada Major Business
2.5.3 Teva Canada β1 Adrenoceptor Agonists Product and Solutions
2.5.4 Teva Canada β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Teva Canada Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer β1 Adrenoceptor Agonists Product and Solutions
2.6.4 Pfizer β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Bedford Laboratories
2.7.1 Bedford Laboratories Details
2.7.2 Bedford Laboratories Major Business
2.7.3 Bedford Laboratories β1 Adrenoceptor Agonists Product and Solutions
2.7.4 Bedford Laboratories β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Bedford Laboratories Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis β1 Adrenoceptor Agonists Product and Solutions
2.8.4 Novartis β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Sterimax
2.9.1 Sterimax Details
2.9.2 Sterimax Major Business
2.9.3 Sterimax β1 Adrenoceptor Agonists Product and Solutions
2.9.4 Sterimax β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Sterimax Recent Developments and Future Plans
2.10 Teligent
2.10.1 Teligent Details
2.10.2 Teligent Major Business
2.10.3 Teligent β1 Adrenoceptor Agonists Product and Solutions
2.10.4 Teligent β1 Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Teligent Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global β1 Adrenoceptor Agonists Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 β1 Adrenoceptor Agonists Players Market Share
3.2.2 Top 10 β1 Adrenoceptor Agonists Players Market Share
3.2.3 Market Competition Trend
3.3 β1 Adrenoceptor Agonists Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global β1 Adrenoceptor Agonists Revenue and Market Share by Type (2016-2021)
4.2 Global β1 Adrenoceptor Agonists Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global β1 Adrenoceptor Agonists Revenue Market Share by Application (2016-2021)
5.2 β1 Adrenoceptor Agonists Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America β1 Adrenoceptor Agonists Revenue by Type (2016-2026)
6.2 North America β1 Adrenoceptor Agonists Revenue by Application (2016-2026)
6.3 North America β1 Adrenoceptor Agonists Market Size by Country
6.3.1 North America β1 Adrenoceptor Agonists Revenue by Country (2016-2026)
6.3.2 United States β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
6.3.3 Canada β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
6.3.4 Mexico β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe β1 Adrenoceptor Agonists Revenue by Type (2016-2026)
7.2 Europe β1 Adrenoceptor Agonists Revenue by Application (2016-2026)
7.3 Europe β1 Adrenoceptor Agonists Market Size by Country
7.3.1 Europe β1 Adrenoceptor Agonists Revenue by Country (2016-2026)
7.3.2 Germany β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
7.3.3 France β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
7.3.4 United Kingdom β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
7.3.5 Russia β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
7.3.6 Italy β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific β1 Adrenoceptor Agonists Revenue by Type (2016-2026)
8.2 Asia-Pacific β1 Adrenoceptor Agonists Revenue by Application (2016-2026)
8.3 Asia-Pacific β1 Adrenoceptor Agonists Market Size by Region
8.3.1 Asia-Pacific β1 Adrenoceptor Agonists Revenue by Region (2016-2026)
8.3.2 China β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
8.3.3 Japan β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
8.3.4 South Korea β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
8.3.5 India β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
8.3.7 Australia β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America β1 Adrenoceptor Agonists Revenue by Type (2016-2026)
9.2 South America β1 Adrenoceptor Agonists Revenue by Application (2016-2026)
9.3 South America β1 Adrenoceptor Agonists Market Size by Country
9.3.1 South America β1 Adrenoceptor Agonists Revenue by Country (2016-2026)
9.3.2 Brazil β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
9.3.3 Argentina β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa β1 Adrenoceptor Agonists Revenue by Type (2016-2026)
10.2 Middle East & Africa β1 Adrenoceptor Agonists Revenue by Application (2016-2026)
10.3 Middle East & Africa β1 Adrenoceptor Agonists Market Size by Country
10.3.1 Middle East & Africa β1 Adrenoceptor Agonists Revenue by Country (2016-2026)
10.3.2 Turkey β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
10.3.4 UAE β1 Adrenoceptor Agonists Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global β1 Adrenoceptor Agonists Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global β1 Adrenoceptor Agonists Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market β1 Adrenoceptor Agonists Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global β1 Adrenoceptor Agonists Revenue (USD Million) by Region (2016-2021)
Table 5. Global β1 Adrenoceptor Agonists Revenue Market Share by Region (2021-2026)
Table 6. Ivax Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Ivax Pharmaceuticals Major Business
Table 8. Ivax Pharmaceuticals β1 Adrenoceptor Agonists Product and Solutions
Table 9. Ivax Pharmaceuticals β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Physicians Total Care Corporate Information, Head Office, and Major Competitors
Table 11. Physicians Total Care Major Business
Table 12. Physicians Total Care β1 Adrenoceptor Agonists Product and Solutions
Table 13. Physicians Total Care β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Baxter Healthcare Corporate Information, Head Office, and Major Competitors
Table 15. Baxter Healthcare Major Business
Table 16. Baxter Healthcare β1 Adrenoceptor Agonists Product and Solutions
Table 17. Baxter Healthcare β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Sanofi Corporate Information, Head Office, and Major Competitors
Table 19. Sanofi Major Business
Table 20. Sanofi β1 Adrenoceptor Agonists Product and Solutions
Table 21. Sanofi β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Teva Canada Corporate Information, Head Office, and Major Competitors
Table 23. Teva Canada Major Business
Table 24. Teva Canada β1 Adrenoceptor Agonists Product and Solutions
Table 25. Teva Canada β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Pfizer Corporate Information, Head Office, and Major Competitors
Table 27. Pfizer Major Business
Table 28. Pfizer β1 Adrenoceptor Agonists Product and Solutions
Table 29. Pfizer β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Bedford Laboratories Corporate Information, Head Office, and Major Competitors
Table 31. Bedford Laboratories Major Business
Table 32. Bedford Laboratories β1 Adrenoceptor Agonists Product and Solutions
Table 33. Bedford Laboratories β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis β1 Adrenoceptor Agonists Product and Solutions
Table 37. Novartis β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Sterimax Corporate Information, Head Office, and Major Competitors
Table 39. Sterimax Major Business
Table 40. Sterimax β1 Adrenoceptor Agonists Product and Solutions
Table 41. Sterimax β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Teligent Corporate Information, Head Office, and Major Competitors
Table 43. Teligent Major Business
Table 44. Teligent β1 Adrenoceptor Agonists Product and Solutions
Table 45. Teligent β1 Adrenoceptor Agonists Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global β1 Adrenoceptor Agonists Revenue (USD Million) by Players (2019-2021)
Table 47. Global β1 Adrenoceptor Agonists Revenue Share by Players (2019-2021)
Table 48. Breakdown of β1 Adrenoceptor Agonists by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. β1 Adrenoceptor Agonists Players Head Office, Products and Services Provided
Table 50. β1 Adrenoceptor Agonists Mergers & Acquisitions in the Past Five Years
Table 51. β1 Adrenoceptor Agonists New Entrants and Expansion Plans
Table 52. Global β1 Adrenoceptor Agonists Revenue (USD Million) by Type (2016-2021)
Table 53. Global β1 Adrenoceptor Agonists Revenue Share by Type (2016-2021)
Table 54. Global β1 Adrenoceptor Agonists Revenue Forecast by Type (2021-2026)
Table 55. Global β1 Adrenoceptor Agonists Revenue by Application (2016-2021)
Table 56. Global β1 Adrenoceptor Agonists Revenue Forecast by Application (2021-2026)
Table 57. North America β1 Adrenoceptor Agonists Revenue by Type (2016-2021) & (USD Million)
Table 58. North America β1 Adrenoceptor Agonists Revenue by Type (2021-2026) & (USD Million)
Table 59. North America β1 Adrenoceptor Agonists Revenue by Application (2016-2021) & (USD Million)
Table 60. North America β1 Adrenoceptor Agonists Revenue by Application (2021-2026) & (USD Million)
Table 61. North America β1 Adrenoceptor Agonists Revenue by Country (2016-2021) & (USD Million)
Table 62. North America β1 Adrenoceptor Agonists Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe β1 Adrenoceptor Agonists Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe β1 Adrenoceptor Agonists Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe β1 Adrenoceptor Agonists Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe β1 Adrenoceptor Agonists Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe β1 Adrenoceptor Agonists Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe β1 Adrenoceptor Agonists Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific β1 Adrenoceptor Agonists Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific β1 Adrenoceptor Agonists Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific β1 Adrenoceptor Agonists Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific β1 Adrenoceptor Agonists Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific β1 Adrenoceptor Agonists Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific β1 Adrenoceptor Agonists Revenue by Region (2021-2026) & (USD Million)
Table 75. South America β1 Adrenoceptor Agonists Revenue by Type (2016-2021) & (USD Million)
Table 76. South America β1 Adrenoceptor Agonists Revenue by Type (2021-2026) & (USD Million)
Table 77. South America β1 Adrenoceptor Agonists Revenue by Application (2016-2021) & (USD Million)
Table 78. South America β1 Adrenoceptor Agonists Revenue by Application (2021-2026) & (USD Million)
Table 79. South America β1 Adrenoceptor Agonists Revenue by Country (2016-2021) & (USD Million)
Table 80. South America β1 Adrenoceptor Agonists Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa β1 Adrenoceptor Agonists Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa β1 Adrenoceptor Agonists Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa β1 Adrenoceptor Agonists Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa β1 Adrenoceptor Agonists Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa β1 Adrenoceptor Agonists Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa β1 Adrenoceptor Agonists Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. β1 Adrenoceptor Agonists Picture
Figure 2. Global β1 Adrenoceptor Agonists Revenue Market Share by Type in 2020
Figure 3. Dobutamine
Figure 4. Denopamine
Figure 5. Xamoterol
Figure 6. Others
Figure 7. β1 Adrenoceptor Agonists Revenue Market Share by Application in 2020
Figure 8. Chronic Heart Failure Picture
Figure 9. Myocardial Infarction Picture
Figure 10. Postoperative Hypotension Picture
Figure 11. Others Picture
Figure 12. Global β1 Adrenoceptor Agonists Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global β1 Adrenoceptor Agonists Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global β1 Adrenoceptor Agonists Revenue Market Share by Region (2016-2026)
Figure 15. Global β1 Adrenoceptor Agonists Revenue Market Share by Region in 2020
Figure 16. North America β1 Adrenoceptor Agonists Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe β1 Adrenoceptor Agonists Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific β1 Adrenoceptor Agonists Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America β1 Adrenoceptor Agonists Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa β1 Adrenoceptor Agonists Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. β1 Adrenoceptor Agonists Market Drivers
Figure 22. β1 Adrenoceptor Agonists Market Restraints
Figure 23. β1 Adrenoceptor Agonists Market Trends
Figure 24. Ivax Pharmaceuticals Recent Developments and Future Plans
Figure 25. Physicians Total Care Recent Developments and Future Plans
Figure 26. Baxter Healthcare Recent Developments and Future Plans
Figure 27. Sanofi Recent Developments and Future Plans
Figure 28. Teva Canada Recent Developments and Future Plans
Figure 29. Pfizer Recent Developments and Future Plans
Figure 30. Bedford Laboratories Recent Developments and Future Plans
Figure 31. Novartis Recent Developments and Future Plans
Figure 32. Sterimax Recent Developments and Future Plans
Figure 33. Teligent Recent Developments and Future Plans
Figure 34. Global β1 Adrenoceptor Agonists Revenue Share by Players in 2020
Figure 35. β1 Adrenoceptor Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players β1 Adrenoceptor Agonists Revenue Market Share in 2020
Figure 37. Global Top 10 Players β1 Adrenoceptor Agonists Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global β1 Adrenoceptor Agonists Revenue Share by Type in 2020
Figure 40. Global β1 Adrenoceptor Agonists Market Share Forecast by Type (2021-2026)
Figure 41. Global β1 Adrenoceptor Agonists Revenue Share by Application in 2020
Figure 42. Global β1 Adrenoceptor Agonists Market Share Forecast by Application (2021-2026)
Figure 43. North America β1 Adrenoceptor Agonists Sales Market Share by Type (2016-2026)
Figure 44. North America β1 Adrenoceptor Agonists Sales Market Share by Application (2016-2026)
Figure 45. North America β1 Adrenoceptor Agonists Revenue Market Share by Country (2016-2026)
Figure 46. United States β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe β1 Adrenoceptor Agonists Sales Market Share by Type (2016-2026)
Figure 50. Europe β1 Adrenoceptor Agonists Sales Market Share by Application (2016-2026)
Figure 51. Europe β1 Adrenoceptor Agonists Revenue Market Share by Country (2016-2026)
Figure 52. Germany β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific β1 Adrenoceptor Agonists Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific β1 Adrenoceptor Agonists Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific β1 Adrenoceptor Agonists Revenue Market Share by Region (2016-2026)
Figure 60. China β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America β1 Adrenoceptor Agonists Sales Market Share by Type (2016-2026)
Figure 67. South America β1 Adrenoceptor Agonists Sales Market Share by Application (2016-2026)
Figure 68. South America β1 Adrenoceptor Agonists Revenue Market Share by Country (2016-2026)
Figure 69. Brazil β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa β1 Adrenoceptor Agonists Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa β1 Adrenoceptor Agonists Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa β1 Adrenoceptor Agonists Revenue Market Share by Country (2016-2026)
Figure 74. Turkey β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE β1 Adrenoceptor Agonists Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界のβアドレナリン受容体作動薬市場 2021：企業別、地域別、種類・用途別 The β Adrenoceptor Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…- 世界のβ2アドレナリン受容体作動薬市場 2021：企業別、地域別、種類・用途別 The β2 Adrenoceptor Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の非選択的アゴニスト市場 2021：企業別、地域別、種類・用途別 The Nonselective Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulatio…
- 世界の選択的アゴニスト市場 2021：企業別、地域別、種類・用途別 The Selective Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations,…
- 世界の緑内障点眼薬市場予測（～2024年）：メーカー別、地域別、種類・用途別 Eye drops used in managing glaucoma decrease eye pressure by helping the eye’s fluid to drain better andor decreasing the amount of fluid made by the eye. Scope of the Report: The worldwide market for Glaucoma Eye Drops is expected to grow at a CAGR of roughly xx% over the next five years, will reac…